Free Trial
→ Gold is soaring. Here’s how to get paid from it (From Investors Alley) (Ad)
NASDAQ:IRD

Opus Genetics 3/31/2025 Earnings Report

Opus Genetics logo
$0.97 -0.02 (-2.18%)
As of 02:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Opus Genetics EPS Results

Actual EPS
-$1.27
Consensus EPS
-$0.34
Beat/Miss
Missed by -$0.93
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
$3.40 million
Expected Revenue
$11.10 million
Beat/Miss
Missed by -$7.70 million
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Date
3/31/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Opus Genetics' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Opus Genetics Earnings Headlines

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...
June 4, 2025 | seekingalpha.com
IRD Opus Genetics, Inc.
June 3, 2025 | seekingalpha.com
Gold is soaring. Here’s how to get paid from it
Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.
June 13, 2025 | Investors Alley (Ad)
Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment
June 2, 2025 | marketwatch.com
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
June 2, 2025 | globenewswire.com
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 18, 2025 | finance.yahoo.com
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles